Close menu




February 24th, 2023 | 15:55 CET

Nvidia, Meta Materials, Plug Power - Invest now in the mega markets of the future

  • metamaterials
  • Innovations
  • Technology
Photo credits: pixabay.com

The current economic and geopolitical situation can be frightening. But every era offers new opportunities. In addition to climate change, which is creating new industries with millions of new jobs, digitalization is booming, with artificial intelligence dominating everything. In addition, new materials are being developed whose properties can solve current challenges in industries such as semiconductors, AI, 5G, aerospace and automotive.

time to read: 4 minutes | Author: Stefan Feulner
ISIN: NVIDIA CORP. DL-_001 | US67066G1040 , Meta Materials Inc. | US59134N1046 , PLUG POWER INC. DL-_01 | US72919P2020

Table of contents:


    Meta Materials - Massive expansion of business areas

    The developer of sustainable, highly functional materials, Meta Materials, has a clear lead over its peer group. The Canadians, who want to redefine the future of coating materials, are researching novel materials that can redirect light, sound, heat and radio waves using special nanotechnology. The technology has multiple applications and can be used worldwide in industries such as 5G communications, health and wellness, aerospace, automotive and renewable energy. Meta Materials has a significant competitive edge with 410 active patent documents, including 251 issued patents and 159 pending patent applications.

    In order to further expand its businesses, the Company announced a USD 100 million capital increase. The proceeds will be used to develop Meta's product portfolio, including NANOWEB, Vlepsis, ARfusion and KolourOptik. In addition, the proceeds will be used for working capital, capital equipment purchases and general and administrative expenses.

    In addition to the offering, Meta Materials also released unaudited fourth-quarter figures. Consolidated revenue for the final quarter was USD 1.4 million, and full-year revenue was USD 10.2 million. The loss for the fourth quarter ranged from USD 21 million to USD 30 million. Thus, for the full year 2022, losses ran between USD 91 million and USD 100 million. At year-end, Meta Materials still had cash and short-term investments of USD 11.8 million.

    A contract for authentication and nano-optics security business with a maximum value of USD 41.5 million over a period of up to 5 years was secured with a G10 central bank customer. "Meta is developing a globally unique metamaterial nano-optical technology and anti-counterfeiting feature for our G10 central bank customer," said George Palikaras, president and CEO. "We are pleased to make progress on this prestigious and important contract with Meta Materials, the largest in the history of banknote security feature development." The global launch of its unique KolourOptik metamaterial nano-optical technology, which combines multi-directional motion, 3D stereo depth, high resolution and multiple colors, is planned for this year.

    Nvidia - Forecasts exceeded

    Positive signs came from leading graphics card maker Nvidia. The chip company was able to publish both revenue and profit above analysts' estimates. In the final quarter of fiscal 2023, which ended in late January, Nvidia posted revenue of USD 6.05 billion, up from USD 7.64 billion in the year-ago period. Profit was USD 1.41 billion, down from USD 3 billion at the end of 2021. For the first quarter of the current fiscal year 2024, the US giant expects revenues of around USD 6.5 billion.

    Positive voices came from several analyst firms following the release. Especially in the boom topic of artificial intelligence, Nvidia Corp. is expected to emerge as the biggest winner among chipmakers after years of focusing on this technology made the Company a preferred supplier for tech companies. The key to the Company's success is that it controls about 80% of the graphics processor market. These specialized chips provide the computing power needed for services like OpenAI's Microsoft-backed chatbot ChatGPT.

    Analysts at US analyst firm Bernstein Research raised their price target from USD 200 to USD 265 on the back of solid quarterly results and an outlook well above market expectations. The buy rating remains "outperform".

    Plug Power - Week of truth

    It will be exciting on Monday next week when the hydrogen specialist opens its books for the fourth quarter and the full year 2022. There were plenty of warnings in the run-up. In the third quarter, for example, sales targets were already cut to USD 845 million. At a strategy update in late January, CEO Andy Marsh warned again that the final quarter would likely be revised downward due to delayed product launches that impact the supply chain. Analysts are projecting revenue in the USD 766 million range, with a loss per share of USD 1.05.

    Next year, however, Plug Power has predicted in the past everything is supposed to get better. For example, the new product units that have fallen behind schedule are to be included in the figures. For the current fiscal year, the US company expects sales of USD 1.4 billion with a gross margin of 10%; in 2026, the forecast is already USD 5 billion with a gross margin of 30%. The CEO's statement on profitability is important. For example, Plug Power is reaching the break-even point expected in 2024 with quarterly sales of USD 600 million and a gross margin of 20%.

    Thus, with the current burn rate, another capital increase and dilution could be on the horizon. As of the end of September 2022, the cash position amounted to USD 1.75 billion. That means that in the first 9 months of last year, it fell by a whopping USD 1.2 billion. From a chart perspective, the 50-day line has just been breached to the downside. The next price target would be the support zone, currently at around EUR 11.


    Nividia was able to convince analyst houses when publishing its annual figures. Plug Power will publish annual figures at the beginning of next week. Meta Materials intends to further push the expansion of its product portfolio.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by André Will-Laudien on June 24th, 2026 | 08:45 CEST

    AI and Chip Sell-Off! Watch Out for SMCI, AMD, and Infineon; First Hydrogen in the Innovation Race

    • Hydrogen
    • cleantech
    • chips
    • AI
    • Innovations
    • Software
    • semiconductor

    The stock market is currently showing no mercy. After months of gains in AI, high-tech, and chip stocks, the market has now shifted into profit-taking mode—and, at times, even sell-off mode. What analysts have been predicting for quite some time is increasingly coming to pass. The global stock market rally, driven by the NASDAQ, is taking its toll. While the long-term earnings outlook may be solid, short-term price surges of up to 2,000% in just 12 months no longer indicate a healthy market trend. So, while it comes as no surprise, it may be unwelcome for many market participants: a sharper downward move—one that, however, also brings new opportunities in its wake. We examine the fundamental framework of the key players and highlight alternatives for getting off to an innovative start today. The stock market keeps turning—just a little slower at times!

    Read

    Commented by Tarik Dede on June 24th, 2026 | 08:05 CEST

    Innovation in Research: Opportunities at Vertex Pharmaceuticals, BioNxt Solutions, and BioNTech

    • Biotechnology
    • Biotech
    • Pharma
    • Innovations

    On social media, you can find all sorts of negative comments and memes about the Pfizer Corporation. One very popular one claims that the company—founded in New York by German immigrants (Karl Pfizer and Karl Erhart)—has never cured a single disease in its 177-year history. This is at least partly true, as Pfizer—particularly for chronic, widespread conditions like high blood pressure or high cholesterol—focuses on treating symptoms rather than the underlying causes. However, it is also true that during World War II, Pfizer was the world's first and largest mass producer of penicillin. Critics level this same accusation against many pharmaceutical companies. Nevertheless, there are numerous companies working on innovative approaches to truly defeat diseases and improve people's lives. And, of course, they also aim to make a lot of money in the process. That is why we are taking a look today at the stocks of Vertex Pharmaceuticals, BioNxt Solutions, and BioNTech.

    Read

    Commented by Nico Popp on June 18th, 2026 | 07:35 CEST

    The Secret Mechanism That Kills Cancer Cells: What Revolution Medicines and Merck & Co. Need to Learn from Vidac Pharma

    • Biotechnology
    • Biotech
    • Pharma
    • Cancer
    • Innovations

    There is, without exaggeration, a looming "patent cliff" of enormous scale: an estimated USD 236 billion in annual revenue losses are forcing the biopharmaceutical industry to find new paths forward. Pharma giants must replace dwindling blockbuster revenues by strategically acquiring innovative oncology platforms, as conventional cancer therapies are increasingly reaching their limits. This innovation pressure is triggering a consolidation wave in which research-driven biotech companies with protected mechanisms of action are moving into the center of potential takeover activity. In particular, intracellular and metabolic treatment approaches are rapidly gaining importance in the fight against treatment-resistant cancers. We take a look at Revolution Medicines' successes and identify the next potential high-flyer.

    Read